28284864|t|Development of a novel near-infrared fluorescent theranostic combretastain A-4 analogue, YK-5-252, to target triple negative breast cancer
28284864|a|The treatment of triple negative breast cancer (TNBC) is a significant challenge to cancer research. The lack of hormone receptors limits the treatment options available to patients with this diagnosis, forcing them to endure prolonged radiation and chemotherapy. Anti-angiogenesis is a chemotherapeutic strategy that targets the vasculature of tumors. Combretastatin A-4 (CA-4) is a well-known vasculature - disrupting agent, which has been shown to effectively kill a variety of cancers through inhibition of tubulin polymerization. Due to its toxicity, small molecule analogues of CA-4 have been sought out. We have designed a novel dual action CA-4 prodrug, YK-5-252, which releases the drug through a disulfide bond cleavage mechanism and contains a near-infrared (NIR) fluorophore, which allows fluorescence monitoring of cleavage. This disulfide linkage causes CA-4 to become effective only when released by glutathione (GSH) reducing the toxicity of the drug while simultaneously releasing the NIR fluorophore. Therefore the prodrug, YK-5-252, represents a novel CA-4 analogue which has reduced toxicity and can be used for theranostics imaging.
28284864	49	60	theranostic	T091	UMLS:C4046052
28284864	61	78	combretastain A-4	T103	UMLS:C0056154
28284864	79	87	analogue	T103	UMLS:C0002776
28284864	89	97	YK-5-252	T103	UMLS:C1254351
28284864	109	138	triple negative breast cancer	T038	UMLS:C3539878
28284864	143	152	treatment	T058	UMLS:C0087111
28284864	156	185	triple negative breast cancer	T038	UMLS:C3539878
28284864	187	191	TNBC	T038	UMLS:C3539878
28284864	223	238	cancer research	T062	UMLS:C1516225
28284864	252	269	hormone receptors	T103	UMLS:C0019929
28284864	281	290	treatment	T058	UMLS:C0087111
28284864	331	340	diagnosis	T033	UMLS:C0011900
28284864	375	384	radiation	T058	UMLS:C1522449
28284864	389	401	chemotherapy	T058	UMLS:C3665472
28284864	403	420	Anti-angiogenesis	T058	UMLS:C0281318
28284864	469	480	vasculature	T017	UMLS:C3714653
28284864	484	490	tumors	T038	UMLS:C0027651
28284864	492	510	Combretastatin A-4	T103	UMLS:C0056154
28284864	512	516	CA-4	T103	UMLS:C0056154
28284864	534	545	vasculature	T017	UMLS:C3714653
28284864	620	627	cancers	T038	UMLS:C0006826
28284864	650	657	tubulin	T103	UMLS:C0041348
28284864	685	693	toxicity	T037	UMLS:C0600688
28284864	710	719	analogues	T103	UMLS:C0002776
28284864	723	727	CA-4	T103	UMLS:C0056154
28284864	787	791	CA-4	T103	UMLS:C0056154
28284864	792	799	prodrug	T103	UMLS:C0033262
28284864	801	809	YK-5-252	T103	UMLS:C1254351
28284864	830	834	drug	T103	UMLS:C1254351
28284864	1007	1011	CA-4	T103	UMLS:C0056154
28284864	1054	1065	glutathione	T103	UMLS:C0017817
28284864	1067	1070	GSH	T103	UMLS:C0017817
28284864	1085	1093	toxicity	T037	UMLS:C0600688
28284864	1101	1105	drug	T103	UMLS:C1254351
28284864	1172	1179	prodrug	T103	UMLS:C0033262
28284864	1181	1189	YK-5-252	T103	UMLS:C1254351
28284864	1210	1214	CA-4	T103	UMLS:C0056154
28284864	1215	1223	analogue	T103	UMLS:C0002776
28284864	1242	1250	toxicity	T037	UMLS:C0600688
28284864	1271	1283	theranostics	T091	UMLS:C4046052
28284864	1284	1291	imaging	T058	UMLS:C0079595